Abstract
Our past research has focused on identifying an effective carrier composed of histidine and lysine for delivery of nucleic acid into cells. For this purpose, we developed histidine-lysine-rich (HK) polymers with specific sequences and branching. We have found that branched HK polymers in complex with Raf-1 siRNA markedly decreased Raf-1 mRNA and induced apoptosis in cell lines in vitro. The primary focus of the present study was to determine an effective carrier to deliver siRNA systemically to tumor xenografts. After comparing HK:Raf-1 polyplexes for their in-vivo efficacy, we investigated in greater detail whether one of these polymers, H3K(+H)4b, in complex with Raf-1 siRNA, inhibited the growth of MDA-MB-435 xenografts. H3K(+H)4b is a four-branched HK peptide whose predominant repeating sequence within the terminal arm is -HHHK-. After the first tail-vein injection in a mouse model, there was a statistically significant reduction in tumor size between the H3K(+H)4b:Raf-1 siRNA-treated and the control groups (P<0.01). By the third injection, there was nearly a 50% reduction in the Raf-1 siRNA-treated group compared to the control siRNA-treated or -untreated group. Consistent with a significant effect of the HK:Raf-1 polyplex on the tumor, there were marked histological changes, increased apoptosis and fewer vessels in the Raf-1 siRNA-treated group. Raf-1 protein within the tumor was significantly decreased after treatment with the HK:Raf-1 siRNA polyplex compared to the control treatment groups. Despite the striking effect on the tumor by the HK Raf-1 siRNA, there was little evidence of toxicity in normal tissues with this therapy. By harnessing the ability to modify the amino-acid sequence and branching of HK polymers, we expect continued development of HK polymers as in-vivo carriers of siRNA.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC . Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806–811.
Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C . Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004; 14: 4975–4977.
Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T . A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004; 64: 3365–3370.
Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ . Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005; 65: 8984–8992.
Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 2007; 104: 5715–5721.
Bartlett DW, Davis ME . Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 2007; 18: 456–468.
Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004; 32: e149.
Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 2005; 11: 944–951.
Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23: 709–717.
Leng Q, Goldgeier L, Zhu J, Cambell P, Ambulos N, Mixson AJ . Histidine-lysine peptides as carriers of nucleic acids. Drug News Perspect 2007; 20: 77–86.
Leng Q, Scaria P, Ioffe OB, Woodle M, Mixson AJ . A branched histidine/lysine peptide, H2K4b, in complex with plasmids encoding antitumor proteins inhibits tumor xenografts. J Gene Med 2006; 8: 1407–1415.
Leng Q, Scaria P, Zhu J, Ambulos N, Campbell P, Mixson AJ . Highly branched HK peptides are effective carriers of siRNA. J Gene Med 2005; 7: 977–986.
Leng Q, Mixson AJ . Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo. Cancer Gene Ther 2005; 12: 682–690.
Chen QR, Zhang L, Luther PW, Mixson AJ . Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles. Nucleic Acids Res 2002; 30: 1338–1345.
Chen QR, Zhang L, Stass SA, Mixson AJ . Co-polymer of histidine and lysine markedly enhances transfection of liposomes. Gene Therapy 2000; 7: 698–704.
Yu W, Pirollo KF, Yu B, Rait A, Xiang L, Huang W et al. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 2004; 32: e48.
Cioca DP, Aoki Y, Kiyosawa K . RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther 2003; 10: 125–133.
Hood J, Granger HJ . Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells. J Biol Chem 1998; 273: 23504–23508.
Rudin CM, Marshall JL, Huang CH, Kindler HL, Zhang C, Kumar D et al. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 2004; 10: 7244–7251.
Pei J, Zhang C, Gokhale PC, Rahman A, Dritschilo A, Ahmad I et al. Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs 2004; 15: 243–253.
Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D . Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995; 270: 25915–25919.
Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA . Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 2003; 162: 933–943.
Khatib AM, Fallavollita L, Wancewicz EV, Monia BP, Brodt P . Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. Cancer Res 2002; 62: 5393–5398.
Leng Q, Kahn J, Zhu J, Scaria P, Mixson J . Needle-like morphology of H2K4b polyplexes associated with increases in transfection in vitro. Cancer Ther 2007; 5B: 193–202.
Chen QR, Zhang L, Stass SA, Mixson AJ . Branched co-polymers of histidine and lysine are efficient carriers of plasmids. Nucleic Acids Res 2001; 29: 1334–1340.
Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002; 296: 2404–2407.
Bellocq NC, Pun SH, Jensen GS, Davis ME . Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 2003; 14: 1122–1132.
Kunath K, Merdan T, Hegener O, Haberlein H, Kissel T . Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J Gene Med 2003; 5: 588–599.
Acknowledgements
We are grateful to Dr Pamela Talalay for her careful reading and useful comments concerning the article. We thank Dr Nicholas Ambulos and Dr Pat Campbell of the Maryland Biopolymer laboratory for synthesizing the peptides in this study. This study was supported by the National Cancer Institute CA70394.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leng, Q., Scaria, P., Lu, P. et al. Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts. Cancer Gene Ther 15, 485–495 (2008). https://doi.org/10.1038/cgt.2008.29
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2008.29
Keywords
This article is cited by
-
Nucleic acid-based drugs for patients with solid tumours
Nature Reviews Clinical Oncology (2024)
-
Harnessing RNAi nanomedicine for precision therapy
Molecular and Cellular Therapies (2014)
-
Buffering Capacity and Size of siRNA Polyplexes Influence Cytokine Levels
Molecular Therapy (2012)
-
Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo
Cancer Gene Therapy (2011)